T he Intensive Care Society (ICS) is the premier professional critical care organisation in the UK. Its Foundation is the Society' s research arm. However, unlike other grant-awarding bodies, the Foundation aims to stimulate, foster and then support a network of critical care units undertaking major trials. The major trials supported by the Foundation, such as TracMan, BALTI-2, Selective Decontamination of the Digestive tract in critically ill patients treated in Intensive Care Units (SuDDICU) and VAsopressin vs Noradrenaline as Initial therapy in Septic sHock (VaNISH), were selected by the Society' s membership. As in previous years, suggesting important areas for clinical trials will be open to any member of the Society and the next selection round will start, hopefully, in the spring of 2010.
Maintaining the Society' s research reputation and fulfilling its aspirations requires two interlinked principal components, a research strategy and an infrastructure to support it. To this end, Professor Monty Mythen convened a small group of academic intensivists with the purpose of developing a national critical care research strategy on behalf of the ICS. The purpose of the strategy is not to push forward individual research projects but rather to offer an inclusive umbrella under which all presently conducted (and hopefully future) critical care research may sit. It was felt that all critical care research could fit within the categories of health services research, hypoxia (ranging from dysfunctional sleep patterns to the respiratory chain in the mitochondria) and sepsis (which affects every system in the body). The advantages of a national strategy are that the major award-granting bodies such as the Wellcome Foundation regard a national strategy as a vital prerequisite for funding, and individual researchers can demonstrate that their particular trial fits within the national strategy. At the moment Monty is pushing forward plans to populate an international board to help develop this strategy further. Through this work they raise the profile of critical care research among major funding organisations, serving to support research throughout our community.
So far, the Foundation has had an excellent track record; it has spent £0.5 million on pilots and other preliminary work and subsequently the supported trials have received £5 million in further grants. This conversion rate of ten to one is exceptional and undoubtedly reflects both the calibre of the projects and the Foundation' s project selection process. However, raising the initial funds, although difficult, is vital, because without funds to support initial project work, the Foundation will fail.
Fundraising involves a wide approach exploring every avenue, however diverse and alternative these may seem. For example, many Society members and their families, together with representatives from the healthcare industry, have battled up Snowdon and over two years have raised almost £50,000. Although we have raffles at the Society' s major social functions, in the South West the trainees also raised a useful sum at one of their meetings. However, if any member wishes to organise Intensive Care Foundation: update
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Finding answers an event and use the Foundation as their nominated charity, please let me know. We are looking for an organiser/team leader for the Foundation' s team in the Great North Run. Together with JPA Europe Limited, who support the Foundation' s fundraising activities, applications are currently underway with ten charitable trusts for continued support of the ICON, SuDDICU and VaNISH studies. The Foundation is adopting a two-pronged approach with regard to donations and major gifts. Understandably, wealthy individuals do not make donations unless they have either a very good understanding and hence belief in the importance of their supported cause, or have personal interest or connection with the cause. The Foundation hopes to raise interest (and hopefully funds) through patients and their relatives who have been in intensive care. In the private sector, Dr John Goldstone at the London Clinic has agreed to bring the Foundation' s work to the patients who are treated on the ICU at the London Clinic. Dr Andy Jones, the Medical Director of the Nuffield Group, has also agreed to insert a leaflet about the Foundation in the discharge pack of patients who are discharged from his hospitals' ICUs. In the NHS, Dr Paul Lawler, who at the tender age of almost 64 has been pulled out of retirement, is organising a Clinical Leadership Committee with the primary aim of increasing levels of donation generally at the local ICU level. This aspect is very important, as one of the key questions asked by potential donors is what funds are raised by the Society' s members. Although members of the Foundation Board and Council contribute, via the gift aid scheme, a total of £3,000 each year, this pales beside asking donors for hundreds or thousands of pounds. Paul' s article about importance of considering legacies will resonate with members over a certain age when recognition of one' s own mortality becomes clearer; supporting the Foundation could be considered when making a will.
The Foundation has been very successful but as it moves into a new phase it will need greater support from the Society' s membership. Any suggestions or offers of assistance are always welcome.
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DH portfolio trials currently looking for centres
The following trials are currently recruiting new centres. All trials listed are on the DH portfolio and therefore qualify for support from the CLRN. If you are interested in recruiting then please contact the person named below. 
